Patents by Inventor James M. McNamara

James M. McNamara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pathogen Detection And Display System
    Publication number: 20240127943
    Abstract: A pathogen detection and display system is configured to discover and display the location of substances of interest, particularly pathogens that can spread infection. The detection and display system can be used in healthcare facilities on surfaces, medical equipment and devices, patients, and staff, for example.
    Type: Application
    Filed: December 15, 2023
    Publication date: April 18, 2024
    Applicant: Cardeya Corporation
    Inventors: Charles R. Sperry, Lawrence J. Pillote, Vincent A. Piucci, Dennis F. McNamara, JR., James M. Wilson, III, Lisa Ruth Stowe, Brett M. Sitzlar, Barbara A. Piucci, David C. Chase
  • Trans-glycosidation process for the synthesis of (2R, 2-alpha-R, 3a)-2-[1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-1,4-oxazine
    Patent number: 6395898
    Abstract: The present invention is concerned with novel processes for the preparation of (2R, 2-alpha-R, 3a)-2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-1,4-oxazine. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: May 28, 2002
    Assignee: Merck & Co. Inc.
    Inventors: James M. McNamara, Matthew M. Zhao
  • Trans-glycosidation process for the synthesis of (2R, 2-alpha-R, 3a) -2-(1- (3,5-bis(trifluoromethyl) phenyl) ethoxy ) -3- (4-fluorophenyl) -1, 4-oxazine
    Publication number: 20020022725
    Abstract: The present invention is concerned with novel processes for the preparation of (2R, 2-alpha-R, 3a)-2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-1,4-oxazine. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity.
    Type: Application
    Filed: June 8, 2001
    Publication date: February 21, 2002
    Inventors: James M. McNamara, Matthew M. Zhao
  • Process for the preparation of leukotriene antagonists
    Patent number: 6320052
    Abstract: The present invention relates to a process for the preparation of a compound of formula (I) or a sodium salt thereof wherein HET is 7-chloroquinolin-2-yl or 6,7-difluoroquinolin-2-yl, which comprises: reacting the dilithium dianion of 1-(mercapto-methyl)cyclopropaneacetic acid with a compound of formula (II) wherein HET is as defined above and L is arylsulfonyl or alkylsulfonyl. The invention further provides the dicyclohexylamine salt of a compound of formula (I).
    Type: Grant
    Filed: March 22, 1999
    Date of Patent: November 20, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mahadevan Bhupathy, Daniel R. Sidler, James M. McNamara, Ralph P. Volante, James Bergan
  • Stereospecific bioconversion of benzyl acetoacetate to benzyl-(s)-(+)-hydroxybutyrate
    Patent number: 5958743
    Abstract: A bioconversion process where benzyl acetoacetate is converted to benzyl-(S)-(+)-3-hydroxybutyrate.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: September 28, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Michel Chartrain, James M. McNamara
  • Pyridyl ethylation of lactams
    Patent number: 5665882
    Abstract: The invention is a highly efficient synthesis for making compounds of formula: ##STR1## wherein n=0, 1, R is C.sub.1-4 alkyl or benzyl; andR.sup.1, when present, is C.sub.1-4 alkyl, OH, O--C.sub.1-4 alkyl or S--C.sub.1-4 alkyl. The process involves silane-mediated conjugation of 4-vinylpyridine to a substituted lactam.
    Type: Grant
    Filed: August 29, 1996
    Date of Patent: September 9, 1997
    Assignee: Merck & Co., Inc.
    Inventors: John Y. L. Chung, Dalian Zhao, James M. McNamara, David L. Hughes
  • Process for the preparation of leukotriene anatgonists
    Patent number: 5614632
    Abstract: The present invention relates to a process for the preparation of a compound of formula (I) or a sodium salt thereof ##STR1## wherein HET is 7-chloroquinolin-2-yl or 6,7-difluoroquinolin-2-yl, which comprises: reacting the dilithium dianion of 1-(mercaptomethyl)cyclopropaneacetic acid with a compound of formula (II) ##STR2## wherein HET is as defined above and L is arylsulfonyl or alkylsulfonyl. The invention further provides the dicyclohexylamine salt of a compound of formula (I).
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: March 25, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Mahadevan Bhupathy, James M. McNamara, Daniel R. Sidler, Ralph P. Volante, James Bergan
  • Process for unsymmetrical dithioacetals and dithioketals
    Patent number: 4883878
    Abstract: This invention relates to a novel process for preparing unsymmetrical dithioacetals and dithioketals from aryl aldehydes and ketones.
    Type: Grant
    Filed: February 8, 1988
    Date of Patent: November 28, 1989
    Assignee: Merck & Co. Inc.
    Inventors: Joseph S. Amato, James M. McNamara, Johnnie L. Leazer, Jr., Paul J. Reider, Robert A. Reamer
  • Process for preparing HMG-CoA reductase inhibitors with a 3,5-dihydroxypentanoate subunit
    Patent number: 4645854
    Abstract: A stereoselective process for the preparation of antihypercholesterolemic agents of the HMG-CoA reductase inhibitor type comprises treatment of an intermediate .beta.-hydroxyketone with a trialkylborane and sodium borohydride at low temperatures.
    Type: Grant
    Filed: April 25, 1985
    Date of Patent: February 24, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Thomas R. Verhoeven, James M. McNamara, Meyer Sletzinger
  • Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
    Patent number: 4611067
    Abstract: This invention relates to a novel process for the preparation of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase inhibitors which contain a 4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one moiety, such as compactin and mevinolin, by utilizing an alkyl 4-cyano-3(R)-hydroxybutanoate as a chiral synthon for the stereospecific introduction of the 4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one moiety.
    Type: Grant
    Filed: January 31, 1985
    Date of Patent: September 9, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Ralph P. Volante, Thomas R. Verhoeven, Meyer Sletzinger, James M. McNamara, Thomas M. H. Liu, Edward G. Corley
  • Process for the preparation of HMG-CoA reductase inhibitors
    Patent number: 4582914
    Abstract: This invention relates to a novel process for the preparation of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase inhibitors which contain a 4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one moiety, such as compactin and mevinolin, by utilizing an alkyl 4-halo-3(S)-hydroxybutanoate as a chiral synthon for the stereospecific introduction of the 4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one moiety.
    Type: Grant
    Filed: January 31, 1985
    Date of Patent: April 15, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Ralph P. Volante, Thomas R. Verhoeven, Meyer Sletzinger, James M. McNamara, Thomas M. H. Liu, Edward G. Corley